Abstract
Red blood cell distribution width (RDW) is an inexpensive marker of anisocytosis easily available in the standard complete blood cell count. Besides its traditional use in the differential diagnosis of anemias, RDW values reflect abnormalities in erythropoiesis and red blood cell metabolism related to aging, sex, ethnicity, systemic inflammatory state, and oxidative stress. Thus, higher RDW values are common findings in several acute clinical conditions and chronic diseases. Increasing evidence suggests a prognostic role of higher RDW levels in many cardiovascular diseases. Among them, we aimed to review current literature focusing on the possible relation between RDW and atrial fibrillation (AF). Since aging, inflammation, and atrial substrate remodeling have a well-established role in AF pathogenesis, AF burden, and patient prognosis, we analyzed available data exploring the possible use of RDW in identifying patients at higher risk of AF and as a biomarker of worse outcomes for AF patients.
Keywords: Ageing, atrial fibrillation, biomarker, inflammation, oxidative stress, red cell distribution width, risk factors, atrial cardiomyopathy.
Current Pharmaceutical Design
Title:Red Cell Distribution Width: A Routinely Available Biomarker with Important Clinical Implications in Patients with Atrial Fibrillation
Volume: 27 Issue: 37
Author(s): Anna C. Valenti, Marco Vitolo, Jacopo F. Imberti, Vincenzo Livio Malavasi and Giuseppe Boriani*
Affiliation:
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena,Italy
Keywords: Ageing, atrial fibrillation, biomarker, inflammation, oxidative stress, red cell distribution width, risk factors, atrial cardiomyopathy.
Abstract: Red blood cell distribution width (RDW) is an inexpensive marker of anisocytosis easily available in the standard complete blood cell count. Besides its traditional use in the differential diagnosis of anemias, RDW values reflect abnormalities in erythropoiesis and red blood cell metabolism related to aging, sex, ethnicity, systemic inflammatory state, and oxidative stress. Thus, higher RDW values are common findings in several acute clinical conditions and chronic diseases. Increasing evidence suggests a prognostic role of higher RDW levels in many cardiovascular diseases. Among them, we aimed to review current literature focusing on the possible relation between RDW and atrial fibrillation (AF). Since aging, inflammation, and atrial substrate remodeling have a well-established role in AF pathogenesis, AF burden, and patient prognosis, we analyzed available data exploring the possible use of RDW in identifying patients at higher risk of AF and as a biomarker of worse outcomes for AF patients.
Export Options
About this article
Cite this article as:
Valenti C. Anna , Vitolo Marco , Imberti F. Jacopo , Malavasi Livio Vincenzo and Boriani Giuseppe*, Red Cell Distribution Width: A Routinely Available Biomarker with Important Clinical Implications in Patients with Atrial Fibrillation, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612827666210211125847
DOI https://dx.doi.org/10.2174/1381612827666210211125847 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Irbesartan: Second Generation of ARB as Metabosartan
Current Hypertension Reviews Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
Current Pharmaceutical Design Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Role of Nuclear Imaging in Cardiac Amyloidosis Management: Clinical Evidence and Review of Literature
Current Medical Imaging Treatment of Fabry Disease: Current and Emerging Strategies
Current Pharmaceutical Biotechnology GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials Multimodality Imaging for Interventional Cardiology
Current Pharmaceutical Design The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets The Involvement of Metallothioneins in Mitochondrial Function and Disease
Current Protein & Peptide Science Ion-Pair Reversed-Phase Denaturing HPLC-Based Biotechnology as a Tool for Genetic Analysis
Current Pharmaceutical Analysis Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Patent Selections
Recent Patents on Cardiovascular Drug Discovery Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Current Pharmaceutical Design